Immunotherapy for tuberculous pericarditis

New England Journal of Medicine

Volumn 371, Issue 12, 2014, Pages 1155-1157

  Chaisson, Richard E ^a   Post, Wendy S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; MYCOBACTERIUM VACCINE; PLACEBO; PREDNISOLONE;

BACTERIUM IDENTIFICATION; CANCER RISK; DRUG RESPONSE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTION RISK; MEDICAL RESEARCH; MYCOBACTERIUM INDICUS PRANII; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SYNDROME DELINEATION; TREATMENT RESPONSE; TUBERCULOUS PERICARDITIS; FEMALE; MALE; MYCOBACTERIUM; NOTE;

FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOTHERAPY; MALE; MYCOBACTERIUM; PERICARDITIS, TUBERCULOUS; PREDNISOLONE;

EID: 84907386020     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1409356     Document Type: Editorial

References (10)

1. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
2. Treatment of tuberculosis. 4th ed. Geneva: World Health Organization, 2010.
3. Maisch B, Seferović PM, Ristić AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary. Eur Heart J 2004;25:587-610.
4. Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014;371:1121-30.
5. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987; 2:1418-22.
6. Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000;84:183-8.
7. Martinson NA, Karstaedt A, Venter WD, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007;21:2043-50.
8. Kendrick MA, Comstock GW. BCG vaccination and the subsequent development of cancer in humans. J Natl Cancer Inst 1981;66:431-7.
9. Chaisson RE, Martinson NA. Tuberculosis in Africa - combating an HIV-driven crisis. N Engl J Med 2008;358:1089-92.
10. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009;23:631-6.